COVID-19 patient serum less potently inhibits ACE2-RBD binding for various SARS-CoV-2 RBD mutants
D Junker, A Dulovic, M Becker, TR Wagner… - Scientific Reports, 2022 - nature.com
As global vaccination campaigns against SARS-CoV-2 proceed, there is particular interest
in the longevity of immune protection, especially with regard to increasingly infectious virus …
in the longevity of immune protection, especially with regard to increasingly infectious virus …
[PDF][PDF] The immunopathobiology of SARS-CoV-2 infection
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can lead to
coronavirus disease 2019 (COVID-19). Virus-specific immunity controls infection …
coronavirus disease 2019 (COVID-19). Virus-specific immunity controls infection …
Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view
A Najmeddin, MB Shapourabadi, M Behdani… - … et Biophysica Acta (BBA …, 2021 - Elsevier
Abstract Background Since December 2019, the newly emerged SARS-CoV-2 virus
continues to infect humans and many people died from severe Covid-19 during the last 2 …
continues to infect humans and many people died from severe Covid-19 during the last 2 …
[HTML][HTML] What we learned in the past year in managing our COVID-19 patients in intensive care units?
Coronavirus disease 2019 is a pandemic, was first recognized at Wuhan province, China in
December 2019. The disease spread quickly across the globe, spreading stealthily from …
December 2019. The disease spread quickly across the globe, spreading stealthily from …
Engineered clinical-grade mesenchymal stromal cells combating SARS-CoV-2 omicron variants by secreting effective neutralizing antibodies
Y Wang, T Gao, WT Li, C Tai, Y Xie, D Chen, S Liu… - Cell & Bioscience, 2023 - Springer
Background The emergence of SARS-CoV-2 becomes life-threatening for the older and
immunocompromised individuals, whereas limited treatment is available on these …
immunocompromised individuals, whereas limited treatment is available on these …
Development of potent and effective synthetic SARS-CoV-2 neutralizing nanobodies
MA Stefan, YK Light, JL Schwedler, PR McIlroy… - MAbs, 2021 - Taylor & Francis
The respiratory virus responsible for coronavirus disease 2019 (COVID-19), severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected nearly every aspect of life …
respiratory syndrome coronavirus 2 (SARS-CoV-2), has affected nearly every aspect of life …
[PDF][PDF] 以不变应万变: 高效广谱抗新冠病毒疫苗和药物防控现在和未来的冠状病毒疫情
蓝巧帅， 夏帅， 陆路， 姜世勃 - 中国科学基金, 2022 - nsfc.gov.cn
2019 年末新冠肺炎暴发后迅速在全球范围内蔓延. 为应对新冠肺炎疫情, 国内外的科研工作者
迅速行动起来, 进行抗新冠病毒的疫苗和药物研究. 我们团队近年来一直致力于高效广谱抗冠状 …
迅速行动起来, 进行抗新冠病毒的疫苗和药物研究. 我们团队近年来一直致力于高效广谱抗冠状 …
An update on novel approaches for diagnosis and treatment of SARS-CoV-2 infection
The ongoing pandemic of coronavirus disease 2019 (COVID-19) has made a serious public
health and economic crisis worldwide which united global efforts to develop rapid, precise …
health and economic crisis worldwide which united global efforts to develop rapid, precise …
[HTML][HTML] SARS-CoV-2 antibody neutralization assay platforms based on epitopes sources: Live virus, pseudovirus, and recombinant S glycoprotein RBD
The high virulent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus that
emerged in China at the end of 2019 has generated novel coronavirus disease, coronavirus …
emerged in China at the end of 2019 has generated novel coronavirus disease, coronavirus …
Druggability of cavity pockets within SARS-CoV-2 spike glycoprotein and pharmacophore-based drug discovery
Aim: Virus spike glycoprotein of SARS-CoV-2 is a good target for drug discovery. Objective:
To examine the potential for druggability of spike protein for pharmacophore-based drug …
To examine the potential for druggability of spike protein for pharmacophore-based drug …